ERBB2 and breast cancer: A study by Elamir et al. [123] showed that decorating liposomal membranes with Trastuzumab (TRA), an anti-HER2 monoclonal antibody, increased the liposomes’ cytotoxicity and their cellular uptake by HER2-positive breast cancer cells, compared to control liposomes.